Antigen News and Research

RSS

Cancer triggers scleroderma, shows evidence

Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.

6 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

The exact definition of orphan diseases varies depending on where you are in the world. In the EU it's defined as a prevalence of less than 1 in 2,000, which equates to about 250,000 patients across the EU.

4 Dec 2013

Wrapping in low molecular weight poly can help stabilize hemoglobin

A UConn research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, a discovery that could lead to the development of stable vaccines and affordable artificial blood substitutes.

4 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children's Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

4 Dec 2013

Presence of ERG protein in biopsied prostate tissue increases likelihood of cancer development

Researchers from Weill Cornell Medical College have shown that the presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. The discovery will likely help physicians decide how closely to monitor men potentially at risk for the cancer -- among the most confusing and controversial dilemmas in health care.

4 Dec 2013

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.

3 Dec 2013

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

Health insurance coverage does not increase risky behavior

People with health insurance are more likely to use preventive services such as flu shots and health screenings to reduce their risk of serious illness, but they are no more likely than people without health insurance to engage in risky health behaviors such as smoking or gaining weight, researchers at UC Davis and University of Rochester have found.

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes - which play a central role in the body's immune response - with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA).

26 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Novel urinary antigen test boosts S. pneumoniae CAP detection

Research published in the European Respiratory Journal shows that addition of a serotype-specific urinary antigen detection test to existing diagnostic methods can increase the detection of Streptococcus pneumoniae community-acquired pneumonia by over a third.

25 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

Scientists find link between airborne allergies and risk of blood cancers in women

A team of scientists looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies - in particular to plants, grass and trees - with risk of blood cancers in women.

25 Nov 2013

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.

21 Nov 2013

Antigen News and Research

Cancer triggers scleroderma, shows evidence

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell

Wrapping in low molecular weight poly can help stabilize hemoglobin

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Top cancer research centers to establish new biotechnology company focused on cancer immunotherapy

Presence of ERG protein in biopsied prostate tissue increases likelihood of cancer development

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

Researchers offer promise of strategy for curing HIV infection

Newly identified protein could prove promising new drug target for AIDS

New biomarkers to improve diagnostics of prostate cancer

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Health insurance coverage does not increase risky behavior

UMass Medical School licenses "anti-gal" technology to Agalimmune

Researchers successfully target T lymphocytes which play key role in body's immune response

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Novel urinary antigen test boosts S. pneumoniae CAP detection

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Scientists find link between airborne allergies and risk of blood cancers in women

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News